indication

or the treatment of respiratory tract infections (including acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia); ear, nose and throat infections; gynecological infections; urinary tract infections (including acute uncomplicated gonococcal urethritis) when caused by non penicillinase-producing susceptible strains of the following organisms: gram-positive organisms, e.g., streptococci, pneumococci and staphylococci; gram-negative organisms, e.g., H. influenzae, N. gonorrhoeae, E. coli, P. mirabilis.

pharmacology

Pivampicillin is the pivaloyloxymethyl ester of (the semi-synthetic penicillin) ampicillin. It is an inactive pro-drug, which is converted during its absorption from the gastrointestinal tract to the microbiologically active ampicillin, together with formaldehyde and pivalic acid, by non-specific esterases present in most body tissues. Amounts in excess of 99% of the pivampicillin absorbed are converted to ampicillin within 15 minutes of absorption.

mechanism of action

Ampicillin (the active metabolite of pivampicillin) has a bactericidal action resulting from inhibition of cell wall mucopeptide biosynthesis.

absorption

Absorbed following oral administration.

half life

Approximately 1 hour.

drug interactions

Demeclocycline: Possible antagonism of action

Doxycycline: Possible antagonism of action

Ethinyl Estradiol: This anti-infectious agent could decrease the effect of the oral contraceptive

Mestranol: This anti-infectious agent could decrease the effect of the oral contraceptive

Methacycline: Possible antagonism of action

Methotrexate: The penicillin increases the effect and toxicity of methotrexate

Minocycline: Possible antagonism of action

Oxytetracycline: Possible antagonism of action

Rolitetracycline: Possible antagonism of action

Tetracycline: Possible antagonism of action